Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy
Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy
复制标题
透明质酸基共聚物作为癌症治疗靶向化疗药物载体的构建与评价
DOI：
10.1088/1361-6528/ab884d
复制
发表时间：
2020-04
期刊：
影响因子：
3.5
通讯作者：
Gao Shi
中科院分区：
文献类型：
--
作者：
Tang Yuting;Chen Minglong;Xie Qian;Li Lu;Zhu Lei;Ma Qingjie;Gao Shi
黑色素瘤（MM）是一种高度侵袭性的皮肤癌，治疗方案有限。虽然化疗已被用于晚期黑色素瘤的治疗，但缺乏靶向性、生物相容性差以及严重的副作用仍然阻碍了化疗药物在MM治疗中的广泛应用。本研究开发了一种生物相容性和可生物降解的高分子透明质酸纳米颗粒（HANP），该纳米颗粒包被紫杉醇（PTX），用于MM靶向治疗。结果表明，在生理条件下，37±2.1% （w/w）的PTX能够加载到HANP中，稳定性超过5 d。在体外，HANP/PTX呈现透明质酸酶依赖的药物释放。与游离PTX相比，HANP/PTX对五种不同癌细胞的生长抑制作用高6-75倍，而对正常细胞的毒性最小。经10 mg kg−1等量PTX静脉注射后，HANP/PTX显著消融小鼠模型中的MM肿瘤生长。18f -氟-2-脱氧-d -葡萄糖（FDG）正电子发射断层扫描（PET）成像证实，肿瘤早在初始治疗后7天就开始对HANP/PTX产生反应，这将显著有利于个性化治疗。综上所述，HANP/PTX纳米复合物作为癌症化疗的转化纳米药物显示出巨大的前景。
Melanoma (MM) is a highly aggressive skin cancer with limited treatment options. Although chemotherapy has been using for advanced melanoma treatment, the lack of targetability, the poor biocompatibility and the severe side effects still hamper the wide applications of chemotherapy agents in MM management. Herein, a biocompatible and biodegradable polymeric hyaluronic acid nanoparticle (HANP) encapsulated with Paclitaxel (PTX) was developed for MM targeted therapy. Our results showed that PTX at 37 ± 2.1% (w/w) was able to be loaded into HANP with over 5 d of stability under physiological conditions. In vitro, HANP/PTX presented hyaluronidase-dependent drug release. Compared to free PTX, HANP/PTX demonstrated a 6–75 times higher growth inhibition in five different cancer cells, while only presenting minimum toxicity to normal cells. After intravenous administration at a 10 mg kg−1 equivalent dose of PTX, HANP/PTX significantly ablated MM tumor growth in a mouse model. As confirmed by 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging, the tumors started to respond to the HANP/PTX as early as 7 d after the initial treatment, which will significantly benefit for personalized treatment. In conclusion, the HANP/PTX nanocomplex demonstrated great promise as a translational nanomedicine for cancer chemotherapy.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
DOI：
10.5402/2012/623139
发表时间：
2012
期刊：
ISRN pharmacology
影响因子：
--
作者：
Surapaneni MS;Das SK;Das NG
通讯作者：
Das NG
影响因子：
11.2
作者：
D. O'Sullivan;Melissa A. O’Neal;B. Felding-Habermann
通讯作者：
D. O'Sullivan;Melissa A. O’Neal;B. Felding-Habermann
一种新型单壁碳纳米管（SWCNT）功能化剂，促进体内联合化疗/热疗
影响因子：
6.7
作者：
Zhang Liwen;Rong Pengfei;Chen Minglong;Gao Shi;Zhu Lei
通讯作者：
Zhu Lei
影响因子：
8
作者：
Xiong W;Peng L;Chen H;Li Q
通讯作者：
Li Q